Professor Albert Ong DM MA FRCP
Professor of Renal Medicine
Department of Infection Immunity & Cardiovascular Disease
University of Sheffield
Beech Hill Road
Tel: +44 (0)114 215 9542
Fax: +44 (0)114 271 3892
Secretary: Ms Jean Lazenby
Tel: +44 (0) 114 215 9509
Albert Ong is Professor of Renal Medicine and Academic Programme Director for Renal Medicine at Sheffield Teaching Hospitals. He attended the University of Oxford, graduating in physiological sciences and clinical medicine and later underwent postgraduate training in medicine and nephrology at University College London (UCL) and Oxford. His research interest in autosomal dominant polycystic kidney disease (ADPKD) started as a Kidney Research UK Senior Research Fellow at the Weatherall Institute of Molecular Medicine, Oxford in the laboratory of Dr Peter Harris. After leaving Oxford, he developed an independent research programme on ADPKD at the University of Sheffield, first as a Senior Lecturer and then as a Wellcome Trust Senior Fellow. The long term research goals of his group have been to define the molecular basis of ADPKD, discover, develop and test new treatments and improve the patient care pathway. He was the main nominated clinical expert to the NICE appraisal panel for the use of Tolvaptan in ADPKD and chaired the Renal Association Working Group which developed the first clinical guidance for its use in the UK. His current external responsibilities include being a member of the ERA-EDTA Scientific Advisory Board, an Editor of Nephrology Dialysis Transplantation and an External Faculty member of the Mayo Clinic Translational PKD Centre (USA).
The major focus of my research group is in Autosomal Dominant Polycystic Kidney Disease (ADPKD). The aim of my laboratory research programme has been to define its molecular and cellular basis. We have identified the critical molecular interactions necessary for the formation, trafficking, regulation and function of the polycystin-1/polycystin-2 ADPKD protein complex and the major changes in cell function and signalling resulting from the disease phenotype. This information is being used to develop new therapeutic approaches using preclinical models with the ultimate goal of translation into man.
The clinical programme is focussed on improving the patient pathway for patients and families with ADPKD. We have established an internationally used UKGTN-approved genetic diagnostic service for PKD1 and PKD2 in collaboration with the Sheffield Genetic Diagnostic Service, a tertiary multidisciplinary PKD clinic based at the Sheffield Kidney Institute which cares for patients in South Yorkshire and have participated in several international clinical studies and trials as the UK lead centre. We are an integral part of the Yorkshire and Humber Genome Medicine Centre (GMC) and the national Renal GeCIP investigating rare genetic causes of kidney disease as part of the UK 100,000 Genomes Project.
I am involved in the development of the next generation of clinical and non-clinical renal scientists and in postgraduate nephrology education locally, nationally and internationally especially in the area of inherited kidney diseases. I am Academic Programme Director for Nephrology, a Board member of the EU FP7 TRANCYST initial training network and the ERA-EDTA Working Group on Inherited Kidney Diseases (WGIKD).
My wider educational interests concern the support and development of nephrology in the developing world. I was previously Chair of the Renal Association International Committee (2009-2013), have hosted an ISN Sister Centre, several International Society of Nephrology (ISN) fellows and am an ISN Educational Ambassador.
National and International Committees
- UK Kidney Research Consortium (UKKRC) Clinical Study Group on Cystic Kidney Diseases - Chair (2009-2014), Vice-Chair (2014-present).
- ADPKD in Europe Consortium - Co-chair (2009-present).
- ERA-EDTA EuroCYST Initiative – Steering Committee (2011), Interim Coordinator (2013-present).
- EU FP7 Marie-Curie TRANCYST Initial Training Network – Board member (2012-present).
- ERA-EDTA Working Group on Inherited Kidney Diseases - Board member (2009-present).
- European ADPKD Forum – Faculty member (2014-present).
- Renal Association International Committee - Chair (2009-2013), Committee member (2014-present).
- Theme Editor, Nephrology Dialysis Transplantation (2016).
- Review Editor, Frontiers in Pharmacology (2015-present).
- Faculty of 1000 Medicine, Nephrology faculty (2008-present).
- Deputy Editor, Nephron Clinical Practice (2008-2012).
- Associate Editor, BMC Nephrology (2008-2012).
- ERA-EDTA Scientific Advisory Board (2016).
- Mayo Translational PKD Centre, Mayo Clinic, Rochester - External Faculty (2015-present).
- National Institute for Clinical Excellence (NICE) Technology Appraisal of Tolvaptan for ADPKD - Nominated Clinical Expert (2013-2015).
- Renal Genomic England Clinical Interpretation Partnership (GeCIP) – Co-chair for Cystic Diseases (2016).
- Federation of European Associations of Patients Affected by Genetic Diseases (FEDERG) - Scientific Council (2014-present).
- International Congress of Chinese Nephrologists - International Advisory Board (2015).
- UK Chinese Life Scientists Society – Fellow (2010-present).
National and International Guidelines
- Renal Association Working Group for Tolvaptan in ADPKD – Chair (2015-present).
- KDIGO Controversies Conference on ADPKD – Invited participant and discussant (2014).
- Improving diagnosis, prognosis and clinical outcomes in ADPKD.
- Understanding the molecular basis of polycystic kidney disease.
- Factors influencing disease progression in experimental models.
For key publications see below. For a full list of publications click here.
- Feng S, Streets AJ, Nesin V, Tran U, Nie H, Onopiuk M, Wessely O, Tsiokas L & Ong A (2017) The Sorting Nexin 3 Retromer Pathway Regulates the Cell Surface Localization and Activity of a Wnt-Activated Polycystin Channel Complex. Journal of the American Society of Nephrology : JASN.
- Ong ACM (2017) Making sense of polycystic kidney disease. The Lancet, 389(10081), 1780-1782.
- Fragiadaki M, Lannoy M, Themanns M, Maurer B, Leonhard WN, Peters DJM, Moriggl R & Ong ACM (2017) STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney International, 91(3), 575-586. View this article in WRRO
- Streets AJ, Magayr TA, Huang L, Vergoz L, Rossetti S, Simms RJ, Harris PC, Peters DJM & Ong ACM (2017) Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression. American Journal of Physiology - Renal Physiology, 312(4), F577-F588. View this article in WRRO
- Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt K-U, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong ACM, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C & Van Biesen W (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 31(3), 337-348. View this article in WRRO
- Xu Y, Streets AJ, Hounslow AM, Tran U, Jean-Alphonse F, Needham AJ, Vilardaga J-P, Wessely O, Williamson MP & Ong ACM (2016) The Polycystin-1, Lipoxygenase, and α-Toxin Domain Regulates Polycystin-1 Trafficking. Journal of the American Society of Nephrology, 27(4), 1159-1173.
- Ong ACM & Harris PC (2015) A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney International, 88(4), 699-710. View this article in WRRO
- Ong ACM, Devuyst O, Knebelmann B & Walz G (2015) Autosomal dominant polycystic kidney disease: the changing face of clinical management. The Lancet, 385(9981), 1993-2002.
- Chang MY & Ong ACM (2013) New treatments for autosomal dominant polycystic kidney disease. British Journal of Clinical Pharmacology, 76(4), 524-535.
- Streets AJ, Wessely O, Peters DJM & Ong ACM (2013) Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation.. Hum Mol Genet, 22(10), 1924-1939.
- Giamarchi A, Feng S, Rodat-Despoix L, Xu YX, Bubenshchikova E, Newby LJ, Hao JZ, Gaudioso C, Crest M, Lupas AN, Honore E, Williamson MP, Obara T, Ong ACM & Delmas P (2010) A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J, 29(7), 1176-1191.
- Ong ACM & Wheatley DN (2003) Polycystic kidney disease--the ciliary connection.. Lancet, 361(9359), 774-776.
- Newby LJ, Streets AJ, Zhao Y, Harris PC, Ward CJ & Ong ACM (2002) Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex.. J Biol Chem, 277(23), 20763-20773. View this article in WRRO
- Ong AC, Harris PC, Davies DR, Pritchard L, Rossetti S, Biddolph S, Vaux DJ, Migone N & Ward CJ (1999) Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue.. Kidney Int, 56(4), 1324-1333.
- Ong AC, Ward CJ, Butler RJ, Biddolph S, Bowker C, Torra R, Pei Y & Harris PC (1999) Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue.. Am J Pathol, 154(6), 1721-1729.
- Ward CJ, Turley H, Ong AC, Comley M, Biddolph S, Chetty R, Ratcliffe PJ, Gattner K & Harris PC (1996) Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney.. Proc Natl Acad Sci U S A, 93(4), 1524-1528.